NCT07219459
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07219459
Title Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure (GDFATHERHCC01)
Acronym GDFATHERHCC01
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors CatalYm GmbH
Indications
Therapies
Age Groups: adult | senior
Covered Countries ITA | DEU

Facility Status City State Zip Country Details
Universitätsklinikum Frankfurt Johann Wolfgang Goethe- Universität RECRUITING Frankfurt 60590 Germany Details
Asst Grande Ospedale Metropolitano Niguarda RECRUITING Milan 20162 Italy Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field